In these two episodes, the experts review the latest pre-clinical and clinical research findings in fibrodysplasia ossificans progressiva (FOP), hypochondroplasia (HCH), osteogenesis imperfecta (OI), and autosomal dominant osteopetrosis. The rare bone disease patient experience is elevated in discussion of the IMPACT survey in OI, as is the role of patient advocacy in keeping patient and caregiver communities informed about research.

This educational activity was developed in partnership between COR2ED and the American Society for Bone and Mineral Research, supported by an independent medical education grant from the Rare Bone Disease Consortium, represented by Alexion, AstraZeneca Rare Disease, by Ipsen and by Kyowa Kirin, who had no input into selection of topics or speakers.